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Background: Presently, pills and injections are the two modes of therapeutic treatment available for tuberculosis
(TB) patients. Many researchers have hypothesized inhalation drug delivery for reducing treatment times and
possibly limiting the insurgence of drug resistance. This study was aimed at identifying and assessing the
preferences of inhalation therapy over injections/pills among pulmonary TB patients.
Method: Cross-sectional study design was used and a sample of 477 participants were recruited at selected three
Directly Observed Treatment Short-Course (DOTS) centers in Bhiwandi city. Data was collected through selfreported questionnaire. Descriptive statistics were reported, and binomial regression models were applied for
data analysis.
Results: The preference of inhalants over pills/injections among pulmonary TB patients was significantly asso
ciated with clinical characteristics. The patients who underwent treatment for more than 1 year were 1.7 times
more likely to prefer inhalants over pills/injections when compared with treatment duration of less than 1 year.
Similarly, patients taking five or more pills/day were 1.7 times more likely to prefer inhalants over pills/in
jections when compared with patients taking 1–4 pills per day.
Conclusion: The study results signify that inhalants could be an acceptable method of drug delivery in this
population of TB patients. Diverse drug delivery options for TB patients may greatly contribute towards TB
treatment adherence.

1. Introduction
Due to the global advancement in biomedicine and research, the
treatment for tuberculosis (TB) is readily available and highly successful
[1]. However, considering drug resistance and the long duration of
treatment, TB remains a serious global threat to the mankind. India not
only shares the highest TB burden in the world accounting for 27% of the
global TB cases [2], but also shares over a quarter of global burden of
multi-drug resistant TB (MDR-TB) cases [3,4]. In 2014, the first National
Anti-Tuberculosis Drug Resistance survey conducted by the Indian
Government in collaboration with the World Health Organization
(WHO) and the United States Agency for International Development
(USAID) showed that, close to 23% of new cases have resistance to any
drug with MDR-TB being detected in 3% of the cases [5]. Lengthy

treatment duration, high pill burden, and strong side effects of TB
medications have been some of the important contributing factors for
non-adherence to TB treatment in India [6].
As of today, pills and injections are the two modes of therapeutic
treatment available for TB patients. These oral or injectable standard
anti-TB drug regimens are well established, relatively inexpensive
therapies, and available free of cost under the government of India’s
Revised National Tuberculosis Control Program (RNTCP) [4,7]. It is
evident from the rise of MDR-TB that, new therapeutic approaches may
be an important avenue to improve adherence to TB medications
[1,6,8,9].
Inhalation therapy, a treatment by inhaling drugs into the respira
tory tract which includes the nose, pharynx, larynx, trachea, bronchi,
and alveoli of the lung could potentially be an underexplored avenue to
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increase TB treatment adherence [1]. Inhalation therapy for TB was
initially investigated in Russia and there has been a rising interest in this
new drug delivery technique [10,11]. Inhalation therapy holds promise
as an alternative route of administration that limits systemic side effects
and delivers high and localized drug concentrations to the site of action
[12]. It uses the alveolar-capillary interface to attain satisfactory sys
temic levels whereas minimizing the risk of systemic toxicity noticed
with parentally delivered doses [13]. Over the last five decades, many
different formulation approaches for inhalation have been investigated.
Micro, nanoparticles, liposomes, proliposomes, and liposphere, with
single and combination drugs have all been tried but mostly limited to
data collected in vitro or from preclinical studies where for the majority,
formulations were found effective in reducing bacterial counts [1,1417]. There have been studies which have used aminoglycosides solution
administered via nebulization for patients with smear-positive pulmo
nary TB. This resulted in inhibition of bacillary growth in alveoli, but it
failed to affect the bacteria inside the macrophages [11]. However, there
are other studies which have similarly attempted the aerosolized drugs
like interferon gamma (IFN-g) among smear and culture positive pul
monary MDR-TB patients and have reported negative smears as well as a
clear radiological improvement and a reduction in the size of the cavi
tary lesions [18,19]. This signifies that mere aerosolizing drug may not
work and for efficient bacteria killing, drugs need to be formulated into
suitable delivery systems ensuring their rapid uptake into the macro
phages which harbor the tubercle bacilli [11]. Furthermore, the complex
host-pathogen relationship and lungs morphology restricts us in
achieving sufficiently high drug concentration and targeting drug to
alveolar region. Patient’s age, breathing pattern, optimized formulation
properties, device performance, and the patient’s understanding/
awareness are key to determine the real fate of aerosol and the final
success of inhaled therapy [13].
Inhalation as a drug delivery method could hold to be a key potential
new drug delivery mode for millions of TB patients. Many biomedicine
and clinical researchers have hypothesized that inhalation drug delivery
may reduce treatment times and possibly limit the insurgence of drug
resistance [10,11,20]. However, before moving towards this innovative
exploration on alternative therapeutic options in the form of inhalants, it
is essential to understand patient preferences towards drug delivery
mechanisms.
The aim of this study was to assess TB patients’ preferences for
inhalation therapy over injections/pills and identify its association with
sociodemographic characteristics (age, gender, and socioeconomic
class) and clinical characteristics (duration of the treatment, pill burden,
experience of side-effects, and medication doses interruption).

2.3. Inclusion and exclusion criteria
Inclusion Criteria
•
•
•
•

Ability to give the written consent
Patients who can understand Hindi Language
18 Years and above
Patients diagnosed with pulmonary TB
Exclusion Criteria

• Patients registered at any other DOTS center in the area except the
three selected DOTS centers.
• Patients who have been undergoing TB treatment for less than one
month
2.4. Sampling
Using the estimated 50% TB medication non-adherence prevalence
rate in India [21], the sample size of 350 was calculated at 80% power
and 0.05 level of significance.
2.5. Measurements
A survey instrument was designed and was administered to the re
spondents to identify the preference of inhalants among pulmonary TB
patients. This survey instrument was translated into Hindi.
2.5.1. Demographic information
The sociodemographic information included age, gender, and so
cioeconomic status. The age was further categorized in three groups
(18–35 years, 36–49 years, and 50 years & above). Socioeconomic status
was identified using Kuppuswammy Scale [22]. This scale is a validated
instrument which uses consumer price index and categorizes the par
ticipant’s socioeconomic class into three categories (upper, middle, and
lower).
2.5.2. Clinical characteristics
This includes variables such as the duration of TB treatment (up to 1
year and more than 1 year), number of pills consumed per day (1–4 pills
per day and 5 or more pills/day), experience of side effects (Yes/No),
and medication dose interruption. Medication dose interruption and its
frequency during the last month was identified using two questions of
the designed survey instrument. The question on medication dose
interruption and its frequency was categorized in three groups; zero
missed doses, missed 1–5 doses, and missed 6 or more doses in the last
one month. The frequency of missing doses was decided based on the
patterns of interruption among tuberculosis patients [23].

2. Materials and methods
2.1. Ethics statement
This study was approved by the Institutional Review Board of the
Penn State College of Medicine, Hershey, Pennsylvania, United States
(#STUDY00010507).

2.5.3. Inhalant preference
The preference of inhalant over pills/injections was measured using
the question, “Would you prefer inhalants over injections/pills”, with a
closed response of Yes/No.

2.2. Study design and settings, and participants

2.6. Data collection

This cross-sectional study was conducted at three Directly Observed
Treatment Short-course (DOTS) centers in Bhiwandi City (15 miles
North-east of Mumbai) of Maharashtra state, in Western India. These
three DOTS centers were located at Shanti Nagar, Gayatri Nagar, and
Nayi Basti slum areas in Bhiwandi City. The DOTS centers selected for
this study conduct primary TB prevention activities, including screening
and outpatient treatment administration services to TB patients in their
respective catchment areas as identified by their names. Only those
participants who visited any of the three DOTS centers during the time
of data collection were recruited in the study.

The study was conducted in two phases. The first phase was con
ducted in September–October 2018 and 212 surveys were completed
during the first phase. A total of 265 surveys were completed in the
second phase which was conducted in September-October 2019. In all a
total of 477 participants were surveyed. The collected data were selfreported and only those participants who visited the three DOTS cen
ters at the point of data collection were recruited in the study. The study
respondents received a peanut and dry fruits nutrition bar package,
irrespective of their decision to participate in the study. Pilot testing of
the study procedures and the survey were conducted at the different
2
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consumed 5 or more pills per day. Around 76% of the patients who
preferred inhalants revealed that they have experienced side-effects
from taking TB medications. Finally, about 20% of the patients who
preferred inhalants had had missed at least one dose of TB medication in
the last month. Among them, 12% patients had missed their doses 1–5
times and 8% had missed their doses more than 6 times in the last month
(Table 2).
After adjusting for age, gender, and socioeconomic class, the pref
erence of inhalants over pills/injections among pulmonary TB patients
were significantly associated with duration of TB treatment, number of
pills taken per day, and reported experience of side-effects from TB
medications. The TB patients who underwent treatment for more than
one year were 1.7 times more likely to prefer inhalants over pills/in
jections (Adjusted OR = 1.684 [95% CI: 1.006–2.818]). Further, pa
tients taking five or more pills per day were 1.7 times more likely to
prefer inhalants over injections/pills when compared with patients
taking 1–4 pills per day (Adjusted OR = 1.681 [95% CI: 1.022–2.763]).
Patients who had experienced side-effects were two times more likely to
prefer inhalants over pills/injections (Adjusted OR = 2.008 [95% CI:
1.185–3.403]) (Table 3).

DOTS centers in Bhiwandi city.
2.7. Statistical analysis
The data were analyzed using Statistical Package for the Social Sci
ences (SPSS) version 26, 2018 software [24]. The following analytical
strategies were employed to examine the preference of inhalants over
injections/pills. First, descriptive statistics were used to present the
basic sample characteristics. Second, multivariable logistic regression
models were applied to identify the association between the preference
of inhalants over injection/pills and other sociodemographic and clin
ical variables. The Wald test was used to determine potential associa
tions at a significance level of p ≤ 0.05.
3. Results
Out of 477 study participants, women comprised more than half
(58%) of the study population. More than two thirds (66%) of the re
spondents 18–35 years of age. Close to 74% of the study participants
belonged to the lower socioeconomic class. The majority (62%) of pa
tients reported a treatment duration of less than one year. More than
two-thirds (72%) of the respondents took 1–4 pills per day and 68% of
the patients experienced side-effects of their TB medication. Among all
study participants, 23% missed their doses in the last month. Among this
group more than 61% patients missed their doses 1–5 times, and the
remaining 39% patients missed their doses ≥ 6 times in the last month.
When asked about the preference of inhalants over pill/injections, 77%
of the total 477 patients responded, and among them, 23% revealed that
they would prefer inhalants over injections/pills (Table 1).
Among the participants who preferred inhalants over injections/
pills, the majority (53%) of them were women. More than two-thirds
(66%) of the respondents who preferred inhalants were in the age
group of 18–35 years. Around 78% of the respondents who preferred
inhalants belonged to the low socioeconomic class. The duration of
treatment among 63% of the patients who preferred inhalants was one
year or less. The majority (66%) of the patients who preferred inhalants
consumed 1–4 pills per day compared to the remaining patients who

Table 2
Sociodemographic and clinical characteristics based on drug delivery prefer
ences among pulmonary tuberculosis patients (n = 477).
Socio-demographics/Clinical
Characteristics

Total
Gender
Male
Female
Age in years
18–35
36–49

Table 1
Socio-demographic and clinical characteristics pulmonary tuberculosis patients
(n = 477).
Socio-demographic and Clinical variables
Gender
Male
Female
Age in years
18–35
36–49
≥50
Socioeconomic Class
Lower
Middle
Upper
Duration of the TB Treatment
Up to 1 year
More than 1 year
Number of Pills Taken Per Day
1–4
≥5
Have Experienced Side Effects of TB Medications
Yes
No
Inhalant Preference over pills/inections
Yes
No
Number of TB Medication Doses Missed in Last One Month
Never Missed
1–5 times
≥6 times

≥50
Socioeconomic Class
Lower

N (%)

Middle

199 (41.7)
278 (58.3)

Upper
Duration of the TB Treatment
Up to 1 year

330 (69.2)
77 (16.1)
70 (14.7)

More than 1 year

361 (75.7)
86 (18.0)
30 (6.3)

Number of Pills Taken Per Day
1–4

295 (61.8)
140 (29.4)

≥5
Have Experienced Side Effects of TB
Medications
Yes

344 (72.1)
133 (27.9)

No

325 (68.1)
146 (30.6)

Number of TB Medication DosesMissed in Last
One Month
Never Missed

109 (22.9)
259 (54.3)

1–5 times

368 (77.1)
66 (13.8)
43 (9.0)

≥6 times

3

Inhalant Preference
overPills/Injections
(N ¼ 477)

Total

Yesn
(%)

Non (%)

n (%)

109
(23)

259 (54)

368 (77)

51
(46.8)
58
(53.2)

105
(40.5)
154
(59.5)

156
(42.4)
212
(57.6)

79
(72.5)
12
(11.0)
18
(16.5)

180
(69.5)
44 (17.0)

259
(70.4)
56 (15.2)

35 (13.5)

53 (14.4)

85 (78)

191
(73.8)
47 (18.1)

276 (75)

21 (8.1)

24 (6.5)

60
(62.5)
36
(37.5)

175
(73.2)
64 (26.8)

235
(70.1)
100
(29.9)

72
(66.1)
37
(33.9)

197
(76.1)
62 (23.9)

269
(73.1)
99 (26.9)

80
(76.2)
25
(23.8)

161
(62.6)
96 (37.4)

241
(66.6)
121
(33.4)

87
(79.8)
13
(11.9)
9 (8.3)

194
(74.9)
42 (16.2)

281
(76.4)
55 (14.9)

23 (8.9)

32 (8.7)

21
(19.3)
3 (2.7)

68 (18.5)
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interest towards inhalation therapy in this study. Hence, while it is
important to focus on new anti-TB drug candidates, it becomes equally
imperative to think simultaneously towards utilizing alternative
methods of drug delivery. These drug delivery methods could poten
tially improve TB medication adherence for the patients with MDR-TB in
India where the standardized treatment regimen is a 6-drug regimen,
with an intensive phase of 6–9 months and a continuation phase of 18
months; for a total treatment duration of about 24–27 months [33].
Another important barrier to TB-medication adherence for TB pa
tients is pill burden. A MDR-TB patient swallows about 14,600 pills in
two years of treatment and undergoes 8 months of painful injections
[34]. Burden of such a huge number of pills also affects patient adher
ence and influences health seeking behavior, with adherence rates
dropping to as low as 20% among patients who must take thirteen or
more pills each day [35]. In our study, the preference for inhalants was
found to be more common among the patients who consumed five or
more pills per day. Hence, innovative drug delivery methods which
could reduce their pill burden and contribute towards effective
compliance.
In addition to the pill burden, side-effects are another cause of
concern associated with TB treatment. Harsh side effects contribute to
wards non-adherence and are potential reasons towards the develop
ment of MDR-TB [6,8,36]. Injectable agents on the other hand, have
been found to be among the most problematic medications in use, cause
a great deal of pain and distress for patients, and are associated with
frequent, serious adverse effects [37]. This study further strengthens this
argument as patients experiencing some form of side effects from TB
medications were found to be more likely to prefer inhalants over pills/
injections.
Overall, duration of treatment, pill burden and painful side effects of
TB medications/injections leads to intentional nonadherence where
patients might skip their doses or cut their number of pills without
informing their provider [38]. Considering these challenges associated
with pills and injections, it becomes imperative to think of future
research strategies regarding the development and design of new drug
delivery methods for TB patients. Inhalation therapy could be one such
method which needs further exploration.
A major therapeutic advance took place in 1997, when tobramycin
designed for inhalation was approved by the U.S. Food and Drug
Administration (FDA) for use in patients with cystic fibrosis (CF) with
chronic Pseudomonas aeruginosa infection [14]. Attracted by the clin
ical benefits observed in CF, there has been a growing interest in the use
of inhaled antibiotics in other lower respiratory tract infections, such as
TB [1]. However, there are also existing practical barriers associated
with the usage of inhalers. These barriers include forgetfulness and poor
routines, inadequate inhaler technique, organizational difficulties (such
as repeat prescriptions), and families not understanding or accepting the
use of an inhaler [39]. There are families and people in India who
believe that that inhalers could stigmatize individuals and also poten
tially become a habit among patients with chronic conditions [40,41].
Additionally, other challenges remain: for instance, the use of special
ized delivery devices could, perhaps, make this therapeutic avenue more
expensive then oral delivery, resulting in a disadvantage for imple
menting this therapy on a large scale, especially in developing countries
like India [1]. Hence, pills and injections should remain available
alongside inhalants.

Table 3
Association of inhalant preference over pills/injections and clinical character
istics among pulmonary tuberculosis patients’ sample (N = 477).
Socio-demographics
and Clinical
Characteristics

Duration of the TB
Treatment
Up to 1 year
More than 1 year
Number of Pills Taken
Per Day
1–4
≥5
Have Experienced Side
Effects of TB
Medications
Yes
No
Number of TB
Medication Doses
missed in the last
month
Never Missed
1–5 times
≥6 times

Inhalant Preference over Pills/Injections (n ¼ 368)
UnadjustedOR
(95%CI)

pvalue

AdjustedOR
(95%CI)

pvalue

Referent
1.641
(0.992–2.712)

–
0.05

Referent
1.684
(1.006–2.818)

–
0.04

Referent
1.633
(1.002–2.661)

–
0.04

1.681
(1.022–2.763)

0.04

1.908
(1.140–3.194)
Referent

0.01

2.008
(1.185–3.403)
Referent

0.01

Referent
0.690
(0.353–1.351)
0.873
(0.388–1.964)

–
0.279

Referent
0.770
(0.386–1.536)
0.893
(0.393–2.032)

–
0.45

–

0.742

–

0.78

OR, Odds ratio; CI, confidence interval; variables- gender, age in years, and
socioeconomic class were adjusted in determining the association of inhalant
preference with each of the clinical variables (duration of TB treatment, number
of pills taken per day, experiencing side-effects and number of TB medication
doses missed in last one month); p ≤ 0.05 statistically significant.

4. Discussion
Several studies examining preferences among various routes of drug
delivery for chronic diseases typically yielded findings in the expected
direction with easier or more convenient routes of administration
preferred over more difficult routes of administration [25-31]. There
have been studies conducted among patients with osteoporosis, diabetes
and multiple sclerosis where respondents were found to prefer oral over
injectable administration [26-28], and inhaled medication over in
jections [29,30]. Some studies have also shown preference for pills over
inhaled medication and injections [30,31]. However, there is a scarcity
of literature on the treatment preferences for the various routes of
administration of TB treatment. The present study focused on largely
unexplored issue, that is, the TB patient’s preference of the use of in
halants over injections/pills as a choice of drug delivery method. Many
of the patients have the experience of using pills and injections for TB
treatment, however this study gave an opportunity for the TB patients to
give their hypothetic preference without direct experience of using in
halants for their TB treatment. The study results revealed that, inhalant
preference over pills/injections had a significant association with clin
ical variables like long treatment duration, high pill burden, and re
ported side-effects of TB medications.
A fundamental problem that hinders more effective TB control is the
ability of TB bacteria to persist in the host and to develop drug resis
tance, often because of poor adherence to lengthy therapy [32]. While
there are several clinical trials which are looking at shorter drug regi
mens, most of the new agents identified as anti-TB drug candidates are
still in the preclinical phases [32]. Rather than focusing on treatment
agents, this study guides us towards inhalants as a potential preference
of drug delivery method among some pulmonary TB patients. Patients
with a longer treatment duration (more than 1 year) have shown more

5. Study limitations
The sample size was small, and data were collected from just three
DOTS centers in Mumbai, therefore the results may not be generalized to
all pulmonary tuberculosis patients. The other limitation of the study is
that the main outcome question about inhalant preference does not
differentiate between injections and pill taking preferences. In addition,
the study had participants with a treatment duration ranging from 6
months to 2 years and did not distinguish between resistant and non4
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resistant patients. Hence, the results cannot be generalized to a partic
ular group of TB patients or to a particular preference for injections or
pills. Future research with specific groups of patients and one with
differentiating injections and pill taking preferences might be useful.
Another limitation of the study was, the inhalant preference question
was given as yes/no question but only 77% of patients responded to that
question and 23% of them did not answer the main outcome question.
There might be a possibility where they did not know the answer,
however the question did not give them the liberty of an option to say
that they did not know. Future studies must consider incorporating the
did not know response so that it can help identify the reasons for missing
cases. Lastly, the study relied on self-report during interviews given by
field staff, and we were not able to map it with the e-nikshay system for
confirmation. This could result in recall or respondent bias.

for Combinatorial Therapy of Antibiotic-Resistant Tuberculosis” For this
we would like to acknolwedge and appreciate the Department of Public
Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania,
United States.
References
[1] Traini D, Young PM. Drug delivery for tuberculosis: is inhaled therapy the key to
success? Ther Deliv 2017;8:819–21. https://doi.org/10.4155/tde-2017-0050.
[2] World Health Organization. Global TB Report. World Health Organization; 2018.
[3] U.S. Agency for International Development. Tuberculosis in India. US Agency Int
Dev 2019. https://www.usaid.gov/global-health/health-areas/tuberculosis/
technical-areas/tuberculosis-india (accessed December 15, 2019).
[4] Revised National Tuberculosis Control Program of India. India TB Report 2019.
New Delhi: Ministry of Health and Family Welfare, India; 2019.
[5] Chatterjee S, Poonawala H, Jain Y. Drug-resistant tuberculosis: is India ready for
the challenge? BMJ Glob Health 2018;3. https://doi.org/10.1136/bmjgh-2018000971.
[6] Munro SA, Lewin SA, Smith HJ, Engel ME, Fretheim A, Volmink J. Patient
Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative
Research. PLOS Med 2007;4:e238. https://doi.org/10.1371/journal.
pmed.0040238.
[7] Revised National Tuberculosis Control Program. TBFacts 2020. https://tbfacts.org/
rntcp/ (accessed April 3, 2020).
[8] Gebremariam MK, Bjune GA, Frich JC. Barriers and facilitators of adherence to TB
treatment in patients on concomitant TB and HIV treatment: a qualitative study.
BMC Public Health 2010;10:651. https://doi.org/10.1186/1471-2458-10-651.
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